Buy Rating for Sana Biotechnology Driven by Promising Clinical Data and Strategic Advancements

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology (SANA – Research Report) today and set a price target of $11.00.

Emily Bodnar’s rating is based on Sana Biotechnology’s promising clinical data and strategic advancements. The company has demonstrated encouraging results with its UP421 therapy, showcasing sustained insulin production and a favorable safety profile in Type 1 diabetes patients. This therapy, which does not require immunosuppression, has shown the ability to overcome immune recognition, evidenced by stable C-peptide levels, a marker for insulin production.
Furthermore, Sana’s ongoing Phase 1 trials for its CAR-T cell therapies, SC291 and SC262, are progressing well, with data expected soon. The company’s pipeline also includes plans to file INDs for additional therapies in 2026, indicating a robust future outlook. These developments, along with the validation of Sana’s HIP technology, underpin Bodnar’s confidence in the company’s potential, leading to the Buy rating.